Oliver Sartor MDLaborde Professor, Cancer Research, Medicine and Urology Departments, Tulane School of Medicine, New Orleans, Louisiana
Dr. Oliver Sartor specializes in the treatment of prostate cancer patients in Louisiana. Dr. Sartor is the Laborde Professor of Cancer Research in the Medicine and Urology Departments of the Tulane School of Medicine. Prior to joining the Tulane faculty, Sartor served as an associate professor in the Lank Genitourinary Oncology Center at Harvard’s Dana-Farber Cancer Institute. He also serves as the chair-elect of the Department of Defense Prostate Cancer Integration Panel, which directs over $70 million in federal funding for prostate cancer research.
Previously, Dr. Sartor was the director of the Stanley S. Scott Cancer Center at Louisiana State University. He was also co-director of the Louisiana Cancer Research Consortium, a state established public-private partnership focused on oncology research in Louisiana.
Dr. Sartor was also an associate professor of medicine at Harvard Medical School.
Sartor is the editor-in-chief of the peer-reviewed, bimonthly journal Clinical Genitourinary Cancer. The journal is dedicated to disseminating cutting edge research to the practicing oncologist. He is the author of more than 100 scientific papers. He received his medical degree from Tulane University, and completed a fellowship with the National Cancer Institute. He is a member of several professional societies, including the American Society of Clinical Oncology, the American Association for Cancer Research, the American Urological Association, and the Society of Urologic Oncology, and board certified in internal medicine and medical oncology.
Oliver Sartor, MD serves as a consultant for Bayer Pharmaceutical, Bristol-Myers Squibb, Celgene Pharmaceutical, Dendreon, Johnson & Johnson, Medivation, Oncogenex Pharmaceutical, Sanofi-Aventis, and Tokai Pharmaceutical.
Oliver Sartor, MD has received research/grant support from Bayer Pharmaceutical, Endocyte Pharmaceutical, Innocrin Pharmaceutical, Johnson & Johnson, and Sanofi-Aventis.
Recent Contributions to PracticeUpdate:
- Adjuvant Radiation Therapy After Radical Prostatectomy Decreases All-Cause Mortality
- Is the Triplet Regimen Standard of Care for Metastatic Castrate-Sensitive Prostate Cancer?
- FDA Approves Second PSMA-Targeted PET Imaging Drug for Men With Prostate Cancer
- Treatment of Metachronous Metastatic Hormone-Sensitive Prostate Cancer With Enzalutamide and ADT
- Molecular Subtypes Associated With Different Responses to Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
- Adding Bone Protective Agents to Enzalutamide and Radium-223 for mCRPC
- Targeted Radioligand Therapy for PSMA+, Metastatic Castration-Resistant Prostate Cancer
- Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer
- Treatment Outcomes in BRCA1/2-, CDK12-, and ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
- Intermediate Clinical Endpoints for Surrogacy in Localised Prostate Cancer